Quarterly report pursuant to Section 13 or 15(d)

Business (Tables)

v3.22.0.1
Business (Tables)
6 Months Ended
Dec. 31, 2021
Schedule Of Entities In Control [Abstract]  
Summary of entities in control
The consolidated financial statements of Benitec Biopharma Inc. are presented in United States dollars and consist of Benitec Biopharma Inc. and its wholly owned subsidiaries:
 
    
Principal place of
business/country of
incorporation
Benitec Biopharma Proprietary Limited (“BBL”)
   Australia
Benitec Australia Proprietary Limited
   Australia
Benitec Limited
   United Kingdom
Benitec, Inc.
   USA
Benitec LLC
   USA
RNAi Therapeutics, Inc.
   USA
Tacere Therapeutics, Inc.
   USA
Benitec IP Holdings, Inc.
   USA